Related Experiment Videos
Prognostic markers in clinically localised prostate cancer
X Z Bai1, J R Masters, N O'Donoghue
1Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530027, China.
International Journal of Oncology
|March 24, 1999
Summary
Immunohistochemical markers like MIB-1 and BCL-2, alongside Gleason score and tumor volume, offer significant prognostic value in radical prostatectomy outcomes. These markers help predict disease progression and patient outcomes more accurately.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Prognostic indicators are crucial for predicting outcomes after radical prostatectomy for prostate cancer.
- Established factors include Gleason score, surgical margins, and tumor volume.
Purpose of the Study:
- To evaluate the prognostic value of specific immunohistochemical markers (P53, BCL-2, p27kip1, PSA, AR, MIB-1).
- To compare their significance against established prognostic variables in prostate cancer patients post-radical prostatectomy.
Main Methods:
- Analysis of five patient groups based on surgical margin status, serum PSA levels, and lymph node micrometastasis.
- Multivariate analysis incorporating immunohistochemical staining results and established prognostic factors.
Main Results:
- Gleason score and tumor volume demonstrated significant prognostic value.
- Immunohistochemical staining for MIB-1 and BCL-2 provided additional independent prognostic significance.
Conclusions:
- MIB-1 and BCL-2 are valuable biomarkers that enhance prognostic accuracy in prostate cancer.
- Combining immunohistochemistry with traditional factors improves prediction of outcomes after radical prostatectomy.